

James D Brenton

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5142681/james-d-brenton-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

19,630
citations

57
h-index

139
g-index

200
ext. papers

23,777
ext. citations

11.5
avg, IF

6.13
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 169 | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , 2012 , 486, 346-52 | 50.4 | 3479 |
| 168 | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. <i>Nature</i> , 2013 , 497, 108-12 | 50.4 | 1220 |
| 167 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017 , 17, 223-238 | 31.3 | 1192 |
| 166 | Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25 | 31.3 | 893 |
| 165 | Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. <i>Science Translational Medicine</i> , 2012 , 4, 136ra68 | 17.5 | 882 |
| 164 | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 75-87 | 21.7 | 706 |
| 163 | Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7350-60 | 2.2 | 696 |
| 162 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79 | 31.3 | 581 |
| 161 | Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , 2009 , 360, 2719-29 | 59.2 | 551 |
| 160 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. <i>Journal of Pathology</i> , 2010 , 221, 49-56 | 9.4 | 485 |
| 159 | Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018 , 10, | 17.5 | 350 |
| 158 | Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. <i>Cancer Cell</i> , 2007 , 11, 498-512 | 24.3 | 305 |
| 157 | The External RNA Controls Consortium: a progress report. <i>Nature Methods</i> , 2005 , 2, 731-4 | 21.6 | 269 |
| 156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 362-70, 370e1-2 | 36.3 | 267 |
| 155 | CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. <i>Nature Communications</i> , 2017 , 8, 14432 | 17.4 | 251 |
| 154 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology, The</i> , 2013 , 14, 853-62 | 21.7 | 248 |
| 153 | Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. <i>PLoS Medicine</i> , 2015 , 12, e1001789 | 11.6 | 230 |

| | | | |
|-----|---|------|-----|
| 152 | High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. <i>Genome Biology</i> , 2007 , 8, R215 | 18.3 | 230 |
| 151 | Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. <i>PLoS ONE</i> , 2014 , 9, e103988 | 3.7 | 228 |
| 150 | Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016 , 2, 247-258 | 5.3 | 192 |
| 149 | Chromosomal instability determines taxane response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8671-6 | 11.5 | 192 |
| 148 | A gene-expression signature to predict survival in breast cancer across independent data sets. <i>Oncogene</i> , 2007 , 26, 1507-16 | 9.2 | 191 |
| 147 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691 | 36.3 | 190 |
| 146 | Differential expression of selected histone modifier genes in human solid cancers. <i>BMC Genomics</i> , 2006 , 7, 90 | 4.5 | 186 |
| 145 | The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. <i>Cancer Cell</i> , 2007 , 12, 514-27 | 24.3 | 171 |
| 144 | Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017 , 147, 267-275 | 4.9 | 163 |
| 143 | Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018 , 8, 304-319 | 24.4 | 157 |
| 142 | Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018 , 50, 1262-1270 | 23.6 | 155 |
| 141 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017 , 3, e173290 | 13.4 | 152 |
| 140 | Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. <i>PLoS Medicine</i> , 2016 , 13, e1002198 | 11.6 | 151 |
| 139 | Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019 , 9, 210-219 | 24.4 | 142 |
| 138 | Evolution of platinum resistance in high-grade serous ovarian cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 1169-74 | 21.7 | 141 |
| 137 | A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. <i>Oncogene</i> , 2005 , 24, 5235-45 | 9.2 | 130 |
| 136 | Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 766-73 | 4 | 127 |
| 135 | Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. <i>Oncogene</i> , 2010 , 29, 4905-13 | 9.2 | 122 |

| | | | |
|-----|---|------|-----|
| 134 | Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. <i>Gut</i> , 2011 , 60, 499-508 | 19.2 | 116 |
| 133 | Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. <i>Human Molecular Genetics</i> , 2008 , 17, 2633-43 | 5.6 | 110 |
| 132 | High resolution melting for mutation scanning of TP53 exons 5-8. <i>BMC Cancer</i> , 2007 , 7, 168 | 4.8 | 108 |
| 131 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 652-7 | 12.9 | 107 |
| 130 | Proposed methods for testing and selecting the ERCC external RNA controls. <i>BMC Genomics</i> , 2005 , 6, 150 | 4.5 | 104 |
| 129 | An imprinting element from the mouse H19 locus functions as a silencer in Drosophila. <i>Nature Genetics</i> , 1997 , 16, 171-3 | 36.3 | 96 |
| 128 | Phylogenetic quantification of intra-tumour heterogeneity. <i>PLoS Computational Biology</i> , 2014 , 10, e1003535 | 5.35 | 91 |
| 127 | Complex stiffness gradient substrates for studying mechanotactic cell migration. <i>Advanced Materials</i> , 2012 , 24, 6059-64 | 24 | 91 |
| 126 | Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. <i>Oncogene</i> , 2007 , 26, 1959-70 | 9.2 | 88 |
| 125 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 2084-2095 | 40 | 88 |
| 124 | Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. <i>Cancer Research</i> , 2002 , 62, 3466-76 | 10.1 | 83 |
| 123 | The pitfalls of platform comparison: DNA copy number array technologies assessed. <i>BMC Genomics</i> , 2009 , 10, 588 | 4.5 | 79 |
| 122 | Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. <i>Radiology</i> , 2012 , 263, 149-59 | 20.5 | 77 |
| 121 | A consensus prognostic gene expression classifier for ER positive breast cancer. <i>Genome Biology</i> , 2006 , 7, R101 | 18.3 | 75 |
| 120 | Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. <i>Genome Biology</i> , 2014 , 15, 526 | 18.3 | 74 |
| 119 | Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. <i>Journal of Pathology</i> , 2012 , 227, 446-55 | 9.4 | 72 |
| 118 | BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. <i>Cancer Research</i> , 2007 , 67, 6725-36 | 10.1 | 72 |
| 117 | The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. <i>PLoS ONE</i> , 2009 , 4, e7988 | 3.7 | 71 |

| | | | |
|-----|---|------|----|
| 116 | Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020 , 52, 582-593 | 36.3 | 64 |
| 115 | Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. <i>British Journal of Cancer</i> , 2011 , 104, 361-8 | 8.7 | 58 |
| 114 | A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. <i>Bioinformatics</i> , 2005 , 21, 3025-33 | 7.2 | 58 |
| 113 | Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 883-892 | 5.1 | 57 |
| 112 | p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020 , 250, 336-345 | 9.4 | 56 |
| 111 | Sequencing Structural Variants in Cancer for Precision Therapeutics. <i>Trends in Genetics</i> , 2016 , 32, 530-548 | 8.5 | 55 |
| 110 | Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. <i>BMC Cancer</i> , 2014 , 14, 891 | 4.8 | 55 |
| 109 | Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. <i>European Radiology</i> , 2010 , 20, 491-6 | 8 | 53 |
| 108 | The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. <i>Journal of Pathology</i> , 2012 , 226, 703-12 | 9.4 | 48 |
| 107 | New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. <i>Journal of Medical Genetics</i> , 2016 , 53, 655-61 | 5.8 | 47 |
| 106 | Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431 | 17.4 | 45 |
| 105 | Microarray segmentation methods significantly influence data precision. <i>Nucleic Acids Research</i> , 2004 , 32, e50 | 20.1 | 45 |
| 104 | Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 21 | 8.3 | 43 |
| 103 | MMASS: an optimized array-based method for assessing CpG island methylation. <i>Nucleic Acids Research</i> , 2006 , 34, e136 | 20.1 | 43 |
| 102 | β integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. <i>Molecular Cancer</i> , 2012 , 11, 36 | 42.1 | 42 |
| 101 | Dynamic contrast-enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease. <i>Magnetic Resonance in Medicine</i> , 2010 , 63, 1044-9 | 4.4 | 42 |
| 100 | Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling. <i>BMC Genomics</i> , 2004 , 5, 9 | 4.5 | 40 |
| 99 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 250-261 | 5.3 | 38 |

| | | | |
|----|--|------|----|
| 98 | Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?. <i>European Radiology</i> , 2009 , 19, 230-5 | 8 | 37 |
| 97 | Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. <i>Clinical Cancer Research</i> , 2014 , 20, 2751-60 | 12.9 | 36 |
| 96 | A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles. <i>ACS Medicinal Chemistry Letters</i> , 2012 , 3, 177-81 | 4.3 | 36 |
| 95 | Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. <i>British Journal of Cancer</i> , 2006 , 94, 1326-32 | 8.7 | 36 |
| 94 | Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer. <i>Angewandte Chemie - International Edition</i> , 2017 , 56, 524-529 | 16.4 | 35 |
| 93 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , 2015 , 9, 115-27 | 7.9 | 35 |
| 92 | Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 5095-101 | 8.3 | 35 |
| 91 | Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. <i>Magnetic Resonance in Medicine</i> , 2009 , 62, 855-61 | 4.4 | 33 |
| 90 | Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. <i>American Journal of Roentgenology</i> , 2010 , 195, 524-7 | 5.4 | 31 |
| 89 | Germline whole exome sequencing and large-scale replication identifies a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , 2017 , 8, 50930-50940 | 3.3 | 30 |
| 88 | Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. <i>BMC Cancer</i> , 2017 , 17, 657 | 4.8 | 29 |
| 87 | Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma. <i>Journal of Pathology</i> , 2016 , 238, 185-96 | 9.4 | 29 |
| 86 | Total syntheses of subereamollines A and B. <i>Organic and Biomolecular Chemistry</i> , 2011 , 9, 62-5 | 3.9 | 29 |
| 85 | Bcl-2 and β -integrin predict survival in a tissue microarray of small cell lung cancer. <i>British Journal of Cancer</i> , 2010 , 103, 1710-5 | 8.7 | 29 |
| 84 | Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. <i>BMC Genomics</i> , 2012 , 13, 719 | 4.5 | 28 |
| 83 | Two novel determinants of etoposide resistance in small cell lung cancer. <i>Cancer Research</i> , 2011 , 71, 4877-87 | 10.1 | 28 |
| 82 | Molecular profiling of breast cancer: portraits but not physiognomy. <i>Breast Cancer Research</i> , 2001 , 3, 77-80 | 8.3 | 28 |
| 81 | Genetic Data From Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517 | 10.1 | 28 |

| | | | |
|----|--|------|----|
| 80 | Metabolic consequences of p300 gene deletion in human colon cancer cells. <i>Cancer Research</i> , 2006 , 66, 7606-14 | 10.1 | 26 |
| 79 | Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. <i>Molecular Oncology</i> , 2015 , 9, 791-805 | 7.9 | 24 |
| 78 | Genomic analysis of the 8p11-12 amplicon in familial breast cancer. <i>International Journal of Cancer</i> , 2007 , 120, 714-7 | 7.5 | 24 |
| 77 | Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020 , 11, 2189 | 17.4 | 23 |
| 76 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019 , 125, 1963-1972 | 6.4 | 22 |
| 75 | Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4. <i>MedChemComm</i> , 2010 , 1, 202 | 5 | 22 |
| 74 | One-stop diagnostic breast clinics: how often are breast cancers missed?. <i>British Journal of Cancer</i> , 2009 , 100, 1873-8 | 8.7 | 22 |
| 73 | Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. <i>Breast Cancer Research</i> , 2005 , 7, 96-9 | 8.3 | 22 |
| 72 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019 , 32, 1834-1846 | 9.8 | 21 |
| 71 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423 | 12.9 | 21 |
| 70 | Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?. <i>Journal of Pathology</i> , 2011 , 225, 157-60 | 9.4 | 21 |
| 69 | Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 956-63 | 8.9 | 21 |
| 68 | A Bayesian adaptive design for biomarker trials with linked treatments. <i>British Journal of Cancer</i> , 2015 , 113, 699-705 | 8.7 | 20 |
| 67 | SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. <i>PLoS ONE</i> , 2016 , 11, e0162698 | 3.7 | 20 |
| 66 | Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 1759-1776 | 8.7 | 19 |
| 65 | A metadata approach for clinical data management in translational genomics studies in breast cancer. <i>BMC Medical Genomics</i> , 2009 , 2, 66 | 3.7 | 18 |
| 64 | Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, 214 | 8.3 | 18 |
| 63 | Molecular pathogenesis of ovarian clear cell carcinoma. <i>Future Oncology</i> , 2015 , 11, 1389-405 | 3.6 | 17 |

| | | | |
|----|---|------|----|
| 62 | Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 1749-59 | 3.4 | 17 |
| 61 | Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020 , 123, 793-802 | 8.7 | 16 |
| 60 | Detection of ctDNA from Dried Blood Spots after DNA Size Selection. <i>Clinical Chemistry</i> , 2020 , 66, 697-705 | 9.5 | 16 |
| 59 | Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer. <i>Insights Into Imaging</i> , 2020 , 11, 94 | 5.6 | 16 |
| 58 | Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5540-5540 | 2.2 | 16 |
| 57 | Total syntheses of the bromotyrosine-derived natural products ianthelline, 5-bromoverongamine and JBIR-44. <i>Tetrahedron Letters</i> , 2010 , 51, 4812-4814 | 2 | 15 |
| 56 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320 | 6.4 | 14 |
| 55 | Predictive cancer genomics--what do we need?. <i>Lancet, The</i> , 2003 , 362, 340-1 | 4.0 | 14 |
| 54 | Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering. <i>Computers in Biology and Medicine</i> , 2020 , 120, 103751 | 7 | 14 |
| 53 | PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSO). <i>Journal of Clinical Oncology</i> , 2016 , 34, 5571-5571 | 2.2 | 12 |
| 52 | Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , 2019 , 293, 374-383 | 20.5 | 11 |
| 51 | Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 1803-1810 | 8.7 | 11 |
| 50 | A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5518-5518 | 2.2 | 11 |
| 49 | Personalising Treatment for High-Grade Serous Ovarian Carcinoma. <i>Clinical Oncology</i> , 2018 , 30, 515-524 | 2.8 | 10 |
| 48 | Slingshot: a PiggyBac based transposon system for tamoxifen-inducible self-inactivating insertional mutagenesis. <i>Nucleic Acids Research</i> , 2010 , 38, e173 | 20.1 | 10 |
| 47 | Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. <i>PLoS ONE</i> , 2014 , 9, e96542 | 3.7 | 9 |
| 46 | TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2021 , 81, 5706-5719 | 10.1 | 9 |
| 45 | Metadata-driven software for clinical trials 2009 , | | 8 |

| | | | |
|----|---|------|---|
| 44 | Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5549-5549 | 2.2 | 8 |
| 43 | Selecting short DNA fragments in plasma improves detection of circulating tumour DNA | | 8 |
| 42 | Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. <i>European Journal of Radiology Open</i> , 2019 , 6, 156-162 | 2.6 | 7 |
| 41 | Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228 | 4 | 7 |
| 40 | Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. <i>Cancers</i> , 2020 , 12, | 6.6 | 7 |
| 39 | Development of Cell-Permeable, Non-Helical Constrained Peptides to Target a Key Protein-Protein Interaction in Ovarian Cancer. <i>Angewandte Chemie</i> , 2017 , 129, 539-544 | 3.6 | 6 |
| 38 | Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. <i>Scientific Reports</i> , 2019 , 9, 10742 | 4.9 | 6 |
| 37 | Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206 | 9.8 | 6 |
| 36 | Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer. <i>European Radiology</i> , 2021 , 31, 3765-3772 | 8 | 6 |
| 35 | You won't believe this old test that does cheap single-cell mutation detection. <i>Journal of Pathology: Clinical Research</i> , 2018 , 4, 149-153 | 5.3 | 5 |
| 34 | The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling. <i>Developmental Biology</i> , 2013 , 379, 16-27 | 3.1 | 5 |
| 33 | Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021 , 77, 67-82 | 12.7 | 5 |
| 32 | Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019 , 8, 2503-2513 | 4.8 | 4 |
| 31 | PathGrid: a service-orientated architecture for microscopy image analysis. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2010 , 368, 3937-52 | 3 | 4 |
| 30 | Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. <i>Molecular Biotechnology</i> , 2005 , 30, 151-4 | 3 | 4 |
| 29 | Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1 (HNF1) transcription factor is imported into the nucleus via a monopartite NLS sequence. <i>Journal of Structural Biology</i> , 2016 , 195, 273-281 | 3.4 | 4 |
| 28 | Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020 , 9, | 7.9 | 3 |
| 27 | Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. <i>Journal of Pathology</i> , 2021 , | 9.4 | 3 |

| | | | |
|----|--|-----|---|
| 26 | Copy-number signatures and mutational processes in ovarian carcinoma | | 3 |
| 25 | Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022 , 41, 12-19 | 3.2 | 3 |
| 24 | Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , 2020 , 101, 40-52 | 3.7 | 2 |
| 23 | Refined characterization of circulating tumor DNA through biological feature integration.. <i>Scientific Reports</i> , 2022 , 12, 1928 | 4.9 | 2 |
| 22 | Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5608-TPS5608 | 2.2 | 2 |
| 21 | DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , | 4 | 2 |
| 20 | Detection of ctDNA from dried blood spots after DNA size selection | | 2 |
| 19 | Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy | | 2 |
| 18 | Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study | | 2 |
| 17 | Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. <i>British Journal of Cancer</i> , 2021 , 124, 1130-1137 | 8.7 | 2 |
| 16 | Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018 , 3, e000408 | 6 | 2 |
| 15 | Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020 , 15, e0235766 | 3.7 | 1 |
| 14 | A metadata-aware application for remote scoring and exchange of tissue microarray images. <i>BMC Bioinformatics</i> , 2013 , 14, 147 | 3.6 | 1 |
| 13 | Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk | | 1 |
| 12 | Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23040-e23040 | 2.2 | 1 |
| 11 | FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 176-186 | 5.2 | 1 |
| 10 | Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma | | 1 |
| 9 | Imprinting and gene silencing in mice and Drosophila. <i>Novartis Foundation Symposium</i> , 1998 , 214, 233-44; discussion 244-50 | | 1 |

| | | | |
|---|--|------|---|
| 8 | The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.. <i>Clinical Cancer Research</i> , 2022 , OF1-OF12 | 12.9 | 1 |
| 7 | New Insights into Tubulin Binders 2011 , 259-278 | | 0 |
| 6 | Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021 , 161, 668-675 | 4.9 | 0 |
| 5 | Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?. <i>Anti-Cancer Drugs</i> , 2016 , 27, 239-44 | 2.4 | 0 |
| 4 | S94 Two novel determinants of etoposide resistance in small cell lung cancer. <i>Thorax</i> , 2010 , 65, A43-A447.3 | | |
| 3 | Genomic Applications in Epithelial Ovarian Malignancies 2015 , 489-502 | | |
| 2 | CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11530-11530 | 2.2 | |
| 1 | Genomic Applications in Ovarian Cancer 2019 , 471-482 | | |